RESILIENCE (National Resilience, Inc.), a new company building the world's most advanced biopharmaceutical manufacturing ecosystem, announced its launch. RESILIENCE has raised over US$800 million of capital following the recent Series B raise of approximately US$750 million. Led by ARCH Venture Partners and 8VC with participation by GV and NEA, investors include public mutual funds, some of the largest U.S.-based pharmaceutical companies, foundations, family offices, and pension funds, among others.
Latham & Watkins LLP represents RESILIENCE in the transaction with a corporate deal team led by Bay Area partners Patrick Pohlen and Miles Jennings, with Bay Area associates Andrew Bertolli and Taimi Jacobson. Advice was also provided on antitrust matters by Washington, D.C. counsel Peter Todaro; and on regulatory matters by Washington, D.C. partners Steven Croley and Jim Barker.